VisionGate Inc.
This article was originally published in Start Up
Executive Summary
In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.
You may also be interested in...
Overcoming Skepticism About Cancer Diagnostics
In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.
Smear Campaign
Pap smears, unlike most other high-volume tests, are manual, subjecting them to human error and inexact judgments. To offset these deficiencies, scientists have been working for nearly three decades to develop automated screening systems, endeavors that until recently were littered with failures.
The Twisted Tale of Automated Pap Smear Screening
After a long history of failures by companies developing new Pap smear testing technologies, a small group of companies seem close to commercializing systems that could transform cytology testin by automating at least a part of the procedure. But these companies have yet to prove to potential users that their instruments save money in the long term and greatly improve quality for a test that most lab users believe already has a relatively low error rate.